Kopran Limited has filed its quarterly compliance certificate with securities depositories, confirming adherence to SEBI regulations governing dematerialization processes for the quarter ended March 31, 2026.

Regulatory Compliance Certification

The pharmaceutical company submitted its certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 to both National Securities Depository Limited and Central Depository Services (India) Limited on April 09, 2026. Company Secretary and Compliance Officer Sunil Sodhani signed the certification document.

Registrar Confirmation

Bigshare Services Pvt. Ltd., serving as Kopran's registrar and share transfer agent, provided supporting documentation for the compliance certificate dated April 08, 2026. The registrar confirmed that securities received from depository participants for dematerialization up to March 31, 2026 were properly processed and confirmed to the depositories.

The registrar's certificate, signed by authorized signatory Akash Shamal, verified that:

• Securities received for dematerialization were accepted or rejected as appropriate
• All securities were properly listed on stock exchanges where existing securities are traded
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members within the required 15-day timeframe

Filing Details

The compliance documentation was simultaneously submitted to stock exchanges where Kopran's shares are listed. The company maintains its listing on both BSE Limited and National Stock Exchange of India Limited.

This quarterly filing represents part of Kopran's ongoing regulatory compliance obligations as a publicly listed pharmaceutical company, ensuring proper handling of dematerialized securities and maintaining transparency with market regulators and depositories.

Kopran Limited has formally announced the resignation of Mr. Adarsh Somani from his position as Non-Executive Non-Independent Director, effective March 17, 2026. The pharmaceutical company disclosed this development to the stock exchanges in compliance with regulatory requirements under SEBI (LODR) Regulations, 2015.

Resignation Details and Background

Mr. Adarsh Somani, holding Director Identification Number (DIN) 00192609, submitted his resignation letter on March 17, 2026. The resignation stems from a Memorandum of Family Settlement dated September 01, 2025, executed among the promoters of the company regarding shareholding and directorship arrangements across various listed and unlisted companies.

Committee Memberships Affected

Along with his directorship, Mr. Somani has also stepped down from his memberships in multiple board committees. His resignation impacts the following committees:

• Stakeholder Relationship Committee
• Risk Management Committee
• Corporate Affairs Committee

Regulatory Compliance and Documentation

Kopran Limited has fulfilled its disclosure obligations by informing both BSE Limited and the National Stock Exchange of India Limited about this board composition change. The company submitted the required information under Regulation 30 of SEBI (LODR) Regulations, 2015, along with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Company Secretary and Compliance Officer Sunil Sodhani (Membership No. FCS 3897) signed the regulatory filings, ensuring proper documentation of the directorship change. The resignation letter from Mr. Somani was attached as Annexure A to the official communication.

Director's Statement

In his resignation letter addressed to the Board of Directors, Mr. Somani expressed appreciation for the opportunity to serve the company. He acknowledged the support and cooperation extended by the Board, management, and colleagues during his tenure with Kopran Limited.

The resignation represents a strategic realignment of directorship roles among the promoter group, following the family settlement agreement executed in September 2025. This development reflects the ongoing corporate governance arrangements within the promoter family structure of the pharmaceutical company.